Drug Profile
GT 002
Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Lund University
- Developer Gabather
- Class Antipsychotics; Small molecules
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia
- Preclinical Cognition disorders; Unspecified
Most Recent Events
- 18 Mar 2024 Pharmacodynamics data from preclinical studies in Schizophrenia released by Gabather
- 18 Mar 2024 Gabather files for patent protection for GT 002 in psychiatric disorders in USA
- 15 Mar 2024 Gabather completes a phase Ib EEG/fMRI target engagement trial in Schizophrenia (In Volunteers) prior to March 2024